Update in genetic susceptibility in melanoma

Annals of Translational Medicine

Volumn 3, Issue 15, 2015, Pages

  Potrony, Miriam ^a   Badenas, Celia ^b,c   Aguilera, Paula ^a,b   Puig Butille, Joan Anton ^b,c   Carrera, Cristina ^a,b   Malvehy, Josep ^a,b   Puig, Susana ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer 1 associated protein 1 (BAP1); Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase inhibitor 2A (CDKN2A); Familial melanoma; Genetic counseling; Melanoma; Melanoma susceptibility; Protection of telomeres 1 (POT1); Telomere

Indexed keywords

EID: 85015496964     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.08.11     Document Type: Review

References (110)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-85.
3. Bleyer A, Viny A, Barr R. Cancer in 15-to 29-year-olds by primary site. Oncologist 2006;11:590-601.
4. Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer 2015;136:E136-45.
5. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
6. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41:45-60.
7. Vink AA, Roza L. Biological consequences of cyclobutane pyrimidine dimers. J Photochem Photobiol B 2001;65:101-4.
8. Hofmann-Wellenhof R, Soyer HP, Wolf IH, et al. Ultraviolet radiation of melanocytic nevi: a dermoscopic study. Arch Dermatol 1998;134:845-50.
9. Stanganelli I, Bauer P, Bucchi L, et al. Critical effects of intense sun exposure on the expression of epiluminescence microscopy features of acquired melanocytic nevi. Arch Dermatol 1997;133:979-82.
10. Tronnier M, Wolff HH. UV-irradiated melanocytic nevi simulating melanoma in situ. Am J Dermatopathol 1995;17:1-6.
11. Carrera C, Puig-Butille JA, Aguilera P, et al. Impact of sunscreens on preventing UVR-induced effects in nevi: in vivo study comparing protection using a physical barrier vs sunscreen. JAMA Dermatol 2013;149:803-13.
12. Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011;29:257-63.
13. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41:28-44.
14. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41:2040-59.
15. Levi F, Randimbison L, Te VC, et al. High constant incidence rates of second cutaneous melanomas. Int J Cancer 2005;117:877-9.
16. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:1647-54.
17. Winship IM, Dudding TE. Lessons from the skin-cutaneous features of familial cancer. Lancet Oncol 2008;9:462-72.
18. Florell SR, Boucher KM, Garibotti G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol 2005;23:7168-77.
19. Anderson DE, Badzioch MD. Hereditary cutaneous malignant melanoma: a 20-year family update. Anticancer Res 1991;11:433-7.
20. Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005;23:3043-51.
21. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115:813-24.
22. Lou Z, Chen J. Cellular senescence and DNA repair. Exp Cell Res 2006;312:2641-6.
23. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-52.
24. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
25. Aoude LG, Wadt KA, Pritchard AL, et al. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res 2015;28:148-60.
26. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007;44:99-106.
27. Potrony M, Puig-Butillé JA, Aguilera P, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol 2014;71:888-95.
28. de Torre C, Garcia-Casado Z, Martinez-Escribano JA, et al. Influence of loss of function MC1R variants in genetic susceptibility of familial melanoma in Spain. Melanoma Res 2010;20:342-8.
29. Pedace L, De Simone P, Castori M, et al. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. Cancer Epidemiol 2011;35:e116-20.
30. Casula M, Muggiano A, Cossu A, et al. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer 2009;9:352.
31. Bruno W, Ghiorzo P, Battistuzzi L, et al. Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol 2009;61:775-82.
32. Nikolaou V, Kang X, Stratigos A, et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol 2011;165:1219-22.
33. Veinalde R, Ozola A, Azarjana K, et al. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation. Melanoma Res 2013;23:221-6.
34. Lukowsky A, Schafer-Hesterberg G, Sterry W, et al. Germline CDKN2A/p16 mutations are rare in multiple primary and familial malignant melanoma in German patients. J Dermatol Sci 2008;49:163-5.
35. Wadt KA, Aoude LG, Krogh L, et al. Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition. PLoS One 2015;10:e0122662.
36. Helgadottir H, Höiom V, Tuominen R, et al. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. Int J Cancer 2015;137:2220-6.
37. Larre Borges A, Cuéllar F, Puig-Butillé JA, et al. CDKN2A mutations in melanoma families from Uruguay. Br J Dermatol 2009;161:536-41.
38. de Ávila AL, Krepischi AC, Moredo LF, et al. Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. Fam Cancer 2014;13:645-9.
39. Grazziotin TC, Rey MC, Bica CG, et al. Genetic variations of patients with familial or multiple melanoma in Southern Brazil. J Eur Acad Dermatol Venereol 2013;27:e179-85.
40. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66:9818-28.
41. Auroy S, Avril MF, Chompret A, et al. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001;32:195-202.
42. Harland M, Cust AE, Badenas C, et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract 2014;12:20.
43. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
44. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-11.
45. Mukherjee B, Delancey JO, Raskin L, et al. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. J Natl Cancer Inst 2012;104:953-6.
46. Ghiorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet 2012;49:164-70.
47. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
48. Helgadottir H, Hoiom V, Jonsson G, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 2014;51:545-52.
49. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
50. Puntervoll HE, Yang XR, Vetti HH, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 2013;50:264-70.
51. Aoude LG, Wadt K, Bojesen A, et al. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS One 2013;8:e72144.
52. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011;48:856-9.
53. Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179.
54. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer 2013;13:153-9.
55. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012;7:e35295.
56. Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. Am J Hum Genet 2013;92:974-80.
57. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
58. Wadt KA, Aoude LG, Johansson P, et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 2015;88:267-72.
59. de la Fouchardière A, Cabaret O, Savin L, et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 2015;88:273-7.
60. Höiom V, Edsgärd D, Helgadottir H, et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer 2013;52:378-84.
61. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
62. Maerker DA, Zeschnigk M, Nelles J, et al. BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol 2014;98:224-7.
63. Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer 2014;53:177-82.
64. Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013;11:1061-71.
65. Wadt K, Choi J, Chung JY, et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 2012;25:815-8.
66. Yang XR, Brown K, Landi MT, et al. Duplication of CXC chemokine genes on chromosome 4q13 in a melanoma-prone family. Pigment Cell Melanoma Res 2012;25:243-7.
67. O'Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol 2010;11:171-81.
68. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005;366:662-4.
69. Han J, Qureshi AA, Prescott J, et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009;129:415-21.
70. Iles MM, Bishop DT, Taylor JC, et al. The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 2014;106.
71. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61.
72. Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 2014;46:478-81.
73. Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 2014;46:482-6.
74. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008;42:301-34.
75. Aoude LG, Pritchard AL, Robles-Espinoza CD, et al. Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 2014;107.
76. Dessinioti C, Antoniou C, Katsambas A, et al. Melanocortin 1 receptor variants: functional role and pigmentary associations. Photochem Photobiol 2011;87:978-87.
77. Williams PF, Olsen CM, Hayward NK, et al. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011;129:1730-40.
78. Flanagan N, Healy E, Ray A, et al. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet 2000;9:2531-7.
79. Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008;122:2753-60.
80. Fargnoli MC, Gandini S, Peris K, et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer 2010;46:1413-20.
81. Córdoba-Lanús E, Hernández-Jiménez JG, Medina-Coello C, et al. MC1R gene variants and sporadic malignant melanoma susceptibility in the Canary Islands population. Arch Dermatol Res 2014;306:51-8.
82. Puig-Butillé JA, Carrera C, Kumar R, et al. Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population. Br J Dermatol 2013;169:804-11.
83. Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480:99-103.
84. Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480:94-8.
85. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006;12:406-14.
86. Ghiorzo P, Pastorino L, Queirolo P, et al. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 2013;26:259-62.
87. Sturm RA, Fox C, McClenahan P, et al. Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. J Invest Dermatol 2014;134:141-9.
88. Berwick M, MacArthur J, Orlow I, et al. MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell Melanoma Res 2014;27:485-8.
89. Ward KA, Lazovich D, Hordinsky MK. Germline melanoma susceptibility and prognostic genes: a review of the literature. J Am Acad Dermatol 2012;67:1055-67.
90. Fernandez LP, Milne RL, Pita G, et al. Pigmentation-related genes and their implication in malignant melanoma susceptibility. Exp Dermatol 2009;18:634-42.
91. Ogbah Z, Badenas C, Harland M, et al. Evaluation of PAX3 genetic variants and nevus number. Pigment Cell Melanoma Res 2013;26:666-76.
92. Planelles D, Nagore E, Moret A, et al. HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor. Br J Dermatol 2006;154:261-6.
93. Peña-Chilet M, Blanquer-Maceiras M, Ibarrola-Villava M, et al. Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer 2013;13:160.
94. Ibarrola-Villava M, Martin-Gonzalez M, Lazaro P, et al. Role of glutathione S-transferases in melanoma susceptibility: association with GSTP1 rs1695 polymorphism. Br J Dermatol 2012;166:1176-83.
95. Iles MM, Law MH, Stacey SN, et al. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet 2013;45:428-32, 432e1.
96. Badenas C, Aguilera P, Puig-Butille JA, et al. Genetic counseling in melanoma. Dermatol Ther 2012;25:397-402.
97. Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012;21:151-61.
98. Udayakumar D, Tsao H. Melanoma genetics: an update on risk-associated genes. Hematol Oncol Clin North Am 2009;23:415-29, vii.
99. Aspinwall LG, Leaf SL, Dola ER, et al. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 2008;17:1510-9.
100. Hansen CB, Wadge LM, Lowstuter K, et al. Clinical germline genetic testing for melanoma. Lancet Oncol 2004;5:314-9.
101. Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000;136:1118-22.
102. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009;61:677.e1-14.
103. Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003;139:607-12.
104. Salerni G, Carrera C, Lovatto L, et al. Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol 2012;67:e17-27.
105. Salerni G, Lovatto L, Carrera C, et al. Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. Arch Dermatol 2011;147:549-55.
106. Aspinwall LG, Taber JM, Leaf SL, et al. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev 2013;22:1687-97.
107. Aspinwall LG, Taber JM, Kohlmann W, et al. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Genet Med 2014;16:846-53.
108. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008;14:7151-7.
109. Vasen HF, Wasser M, van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011;140:850-6.
110. Battaglia A. The Importance of Multidisciplinary Approach in Early Detection of BAP1 Tumor Predisposition Syndrome: Clinical Management and Risk Assessment. Clin Med Insights Oncol 2014;8:37-47.